DarioHealth Corp. (DRIO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. DarioHealth Corp. is a global digital therapeutics (DTx) company providing personalized interventions for chronic conditions (diabetes, hypertension, weight management) and behavioral health. The company operates as a single segment with a "whole-person" health model integrating hardware, AI, and coaching. All share data reflects a 20-for-1 reverse stock split effective August 28, 2025.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $5,584 | $6,752 |
| Gross Profit | $3,200 | $3,882 |
| Gross Margin | 57.3% | 57.5% |
| Operating Loss | $(7,309) | $(9,409) |
| Net Loss | $(8,249) | $(9,227) |
| Net Loss Per Share (Basic/Diluted) | $(1.25) | $(2.87) |
| Cash & Equivalents (End of Period) | $14,977 | $27,854 |
| Short-Term Deposits | $5,035 | $4,214 |
| Long-Term Debt (Callodine Facility) | $30,931 | $30,747 |
| Stockholders' Equity | $62,380 | $73,699 |
| Cash Used in Operating Activities | $(6,025) | $(6,673) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 17.3% to $5.6 million, primarily due to the absence of a non-recurring pharmaceutical partner revenue recognized in Q1 2025. This was partially offset by growth in channel partner and direct-to-consumer sales.
- Expense Reduction: Operating expenses decreased significantly. R&D expenses dropped 41.9% to $2.4 million, and Sales & Marketing expenses fell 16.6% to $4.9 million, driven by post-merger efficiencies and reduced payroll/stock-based compensation.
- Improved Loss Profile: Net loss narrowed by 10.6% to $8.2 million. Non-GAAP adjusted loss improved to $5.3 million from $5.8 million in the prior year.
- Warrant Liability: The Pre-Funded Warrant liability related to the Twill acquisition was fully exercised in February 2026, eliminating the associated fair value remeasurement volatility seen in prior periods.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states there is substantial doubt about the Company's ability to continue as a going concern for twelve months from the issuance date. Current cash on hand is deemed insufficient to fund projected operating requirements without additional financing.
- Liquidity Strategy: The Company entered an At-The-Market (ATM) sales agreement on March 30, 2026, allowing for the sale of up to $20 million of common stock. Subsequent to quarter-end, approximately $54,000 in gross proceeds were generated. The Company also holds a $32.5 million credit facility (Callodine Loan) with principal repayments deferred until May 2028.
- Debt Covenants: The Company previously missed a financial covenant in August 2025 but secured a waiver and amended the agreement in November 2025, replacing the minimum cash covenant with a $10 million minimum unencumbered liquid assets covenant. As of March 31, 2026, the Company was in compliance.
- Risk Factors: Key risks include the need for additional capital, potential inability to meet debt covenants, and geopolitical instability in Israel affecting operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $15 million cash balance against the stated "substantial doubt" regarding the 12-month going concern horizon.
- ATM Execution: Monitor the utilization of the new $20 million ATM facility to determine if it can bridge the funding gap.
- Debt Compliance: Confirm ongoing compliance with the amended Callodine Loan Facility covenants, specifically the $10 million liquid assets threshold.
- Revenue Recurrence: Assess the sustainability of revenue growth without the non-recurring pharmaceutical partner revenue that inflated Q1 2025 figures.
- Share Count: Note the impact of the 20-for-1 reverse split on share count and per-share metrics when comparing to historical data.